Published in Circ Res on November 21, 2008
Atherosclerosis: current pathogenesis and therapeutic options. Nat Med (2011) 4.95
Inflammation, immunity, and hypertension. Hypertension (2010) 3.43
Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation (2010) 1.68
Role of the adaptive immune system in hypertension. Curr Opin Pharmacol (2010) 1.44
Innate and adaptive immunity in atherosclerosis. Semin Immunopathol (2009) 1.40
Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice. J Biol Chem (2010) 1.17
Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev (2010) 0.98
Human vascular smooth muscle cells lack essential costimulatory molecules to activate allogeneic memory T cells. Arterioscler Thromb Vasc Biol (2010) 0.94
Natural killer T cells in lipoprotein metabolism and atherosclerosis. Thromb Haemost (2011) 0.91
Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore) (2015) 0.89
The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells. BMC Immunol (2011) 0.85
TNF superfamily: costimulation and clinical applications. Cell Biol Int (2009) 0.83
The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis. J Biomed Biotechnol (2011) 0.81
T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases. Front Physiol (2012) 0.81
T cells and blood vessels: costimulation turns up the pressure. Circulation (2010) 0.80
OX40-OX40L interaction promotes proliferation and activation of lymphocytes via NFATc1 in ApoE-deficient mice. PLoS One (2013) 0.80
Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst Biol (2012) 0.80
Ox-LDL increases OX40L in endothelial cells through a LOX-1-dependent mechanism. Braz J Med Biol Res (2013) 0.79
Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects. Front Physiol (2014) 0.79
Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS One (2014) 0.77
KV1.3: a new therapeutic target to control vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol (2010) 0.77
Adhesion to substrates induces dendritic cell endothelization and decreases immunological response. Immunobiology (2012) 0.77
Modulation of both activator protein-1 and nuclear factor-kappa B signal transduction of human T cells by amiodarone. Exp Biol Med (Maywood) (2014) 0.77
A novel atherogenic epitope from Mycobacterium tuberculosis heat shock protein 65 enhances atherosclerosis in rabbit and LDL receptor-deficient mice. Heart Vessels (2011) 0.76
Absence of miR-182 Augments Cardiac Allograft Survival. Transplantation (2016) 0.75
Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina. Dis Markers (2014) 0.75
The Roles of CD137 Signaling in Atherosclerosis. Korean Circ J (2016) 0.75
PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma. Cancer Med (2016) 0.75
Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions. Drug Des Devel Ther (2014) 0.75
Immunization of Chlamydia pneumoniae (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development. PLoS One (2013) 0.75
Chronic Kidney Disease Induces Inflammatory CD40+ Monocyte Differentiation via Homocysteine Elevation and DNA Hypomethylation. Circ Res (2016) 0.75
Effects of OX40-OX40L interaction on the nuclear factor of activated T cells c1 in ApoE-deficient mice. Inflammation (2014) 0.75
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
The B7-CD28 superfamily. Nat Rev Immunol (2002) 7.24
CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol (1998) 6.83
A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol (2005) 6.77
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 5.32
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol (2003) 5.01
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44
Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med (2006) 4.28
Innate and acquired immunity in atherogenesis. Nat Med (2002) 4.22
ICOS is essential for effective T-helper-cell responses. Nature (2001) 4.01
Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet (2005) 3.86
Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol (1989) 3.82
Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med (2002) 3.80
CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med (2004) 3.57
T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A (1995) 3.54
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 3.31
Protective role of interleukin-10 in atherosclerosis. Circ Res (1999) 3.28
B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity (1997) 3.22
Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation (2000) 3.17
ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb (1994) 3.11
Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest (1996) 3.10
Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res (2001) 3.07
Molecular basis of T cell inactivation by CTLA-4. Science (1998) 3.00
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J (2006) 2.93
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol (2003) 2.91
Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol (2001) 2.89
T-cell costimulation--biology, therapeutic potential, and challenges. N Engl J Med (2006) 2.81
The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci (2001) 2.75
Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol (1999) 2.73
Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol (2004) 2.59
Transcriptional regulation of th2 differentiation by inducible costimulator. Immunity (2003) 2.56
Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A (2004) 2.50
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 2.49
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med (2002) 2.23
NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol (2007) 2.19
Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation (1998) 2.11
Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest (2003) 1.98
Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev (2007) 1.94
Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol (2006) 1.92
Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med (2003) 1.89
Requirement for CD154 in the progression of atherosclerosis. Nat Med (1999) 1.86
T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A (2005) 1.82
Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J Immunol (2007) 1.82
Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol (2000) 1.80
Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2001) 1.79
The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (1999) 1.77
Role of 4-1BB in immune responses. Semin Immunol (1998) 1.77
Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation (2006) 1.77
Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74
Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp Med (1999) 1.69
Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol (2003) 1.69
In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation (2001) 1.69
CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation (2008) 1.64
Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol (2007) 1.63
Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A (2000) 1.63
Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb (1992) 1.59
Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler Thromb Vasc Biol (2005) 1.58
Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol (2003) 1.57
CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest (2003) 1.52
Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol (2006) 1.42
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation (2007) 1.37
Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity. J Exp Med (2007) 1.36
A new class of reverse signaling costimulators belongs to the TNF family. J Immunol (2007) 1.33
Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol (2006) 1.30
4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol (2004) 1.30
Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol (2001) 1.30
B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation (2004) 1.30
Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen. Proc Natl Acad Sci U S A (2004) 1.27
Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 1.22
Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol (1999) 1.21
Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2006) 1.21
Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med (2000) 1.19
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest (2007) 1.19
Confirmation and high resolution mapping of an atherosclerosis susceptibility gene in mice on Chromosome 1. Mamm Genome (2002) 1.16
The ICOS molecule plays a crucial role in the development of mucosal tolerance. J Immunol (2005) 1.13
Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol (2004) 1.11
Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology (2004) 1.08
Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol (2005) 1.04
OX40 controls functionally different T cell subsets and their resistance to depletion therapy. J Immunol (2007) 1.04
Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc Med (2007) 1.04
ICOS+ Th cells produce distinct cytokines in different mucosal immune responses. Eur J Immunol (2003) 1.03
Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. Atherosclerosis (1997) 1.00
CD28 and ICOS: similar or separate costimulators of T cells? Immunol Lett (2006) 0.98
CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med (2007) 0.98
Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation (1998) 0.98
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol (2008) 5.92
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity (2007) 4.49
Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med (2006) 4.17
Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med (2002) 3.80
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol (2010) 3.51
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol (2006) 3.42
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood (2005) 2.95
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol (2003) 2.91
PD-1 and its ligands in T-cell immunity. Curr Opin Immunol (2007) 2.86
Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med (2008) 2.81
Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol (2006) 2.73
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
Interaction of human PD-L1 and B7-1. Mol Immunol (2008) 2.48
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity (2012) 2.47
Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A (2007) 2.39
Deletion of a conserved Il4 silencer impairs T helper type 1-mediated immunity. Nat Immunol (2004) 2.38
Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity (2013) 2.37
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol (2007) 2.34
The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol (2012) 2.17
The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nat Immunol (2003) 2.17
In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res (2003) 2.12
An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity (2004) 2.00
Silencing of lipid metabolism genes through IRE1α-mediated mRNA decay lowers plasma lipids in mice. Cell Metab (2012) 1.90
IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A (2008) 1.84
T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A (2005) 1.82
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008) 1.82
CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol (2002) 1.78
Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol (2011) 1.77
The cell surface receptor SLAM controls T cell and macrophage functions. J Exp Med (2004) 1.77
Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation (2006) 1.77
CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol (2002) 1.73
CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol (2010) 1.71
Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol (2003) 1.69
B7/CD28-dependent CD4+CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J Immunol (2002) 1.69
Negative co-receptors on lymphocytes. Curr Opin Immunol (2002) 1.66
Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol (2009) 1.66
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.62
Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci U S A (2011) 1.62
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol (2004) 1.60
The B7/CD28 costimulatory family in autoimmunity. Immunol Rev (2005) 1.57
The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol (2003) 1.57
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest (2010) 1.53
SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase. Mol Cell (2013) 1.52
Role of PD-1 in regulating acute infections. Curr Opin Immunol (2010) 1.51
Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol (2011) 1.47
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 1.44
IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol (2012) 1.44
Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol (2005) 1.40
Innate and adaptive immunity in atherosclerosis. Semin Immunopathol (2009) 1.40
PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur J Immunol (2006) 1.38
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation (2007) 1.37
Influence of C3 deficiency on atherosclerosis. Circulation (2002) 1.37
Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol (2009) 1.37
IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis. J Clin Invest (2003) 1.31
T-bet controls pathogenicity of CTLs in the heart by separable effects on migration and effector activity. J Immunol (2006) 1.31
4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol (2004) 1.30
B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation (2004) 1.30
Physiologic control of IDO competence in splenic dendritic cells. J Immunol (2011) 1.29
Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood (2005) 1.28
CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res (2008) 1.26
The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest (2003) 1.26
Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J Immunol (2009) 1.25
PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol (2012) 1.24
Statin-induced Krüppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Invest (2010) 1.23
Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation (2011) 1.20
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest (2007) 1.19
Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur J Immunol (2002) 1.19
Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity (2012) 1.19
The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J Virol (2011) 1.18
Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol (2007) 1.17
The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol (2007) 1.17
The role of OX40 ligand interactions in the development of the Th2 response to the gastrointestinal nematode parasite Heligmosomoides polygyrus. J Immunol (2003) 1.17
BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med (2005) 1.16
A role for the B7-1/B7-2:CD28/CTLA-4 pathway during negative selection. J Immunol (2003) 1.16
Circulatory antigen processing by mucosal dendritic cells controls CD8(+) T cell activation. Immunity (2012) 1.15
ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol (2008) 1.14
The ICOS molecule plays a crucial role in the development of mucosal tolerance. J Immunol (2005) 1.13
The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol (2013) 1.13
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology (2013) 1.13
Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A (2013) 1.10